2023年第59届美国临床肿瘤学会（ASCO）年会将于美国芝加哥当地时间6月2~6日举行，一年一度的学术盛宴将启。ASCO官网已公布会议日程和摘要题目。
【肿瘤资讯】特别整理了壁报交流专场（Poster Discussion Session）、口头摘要专场（Oral Abstract Session）的分子靶向药物与肿瘤生物学研究，与临床医生分享。
壁报交流专场（Poster Discussion Session）
摘要号：3009 | Poster Bd #: 207
新一代CDK4选择性抑制剂PF-07220060在晚期实体瘤患者中的首次人体1/2a期研究，以先前接受过CDK4/6抑制剂和内分泌治疗后进展的HR+、HER2-转移性乳腺癌患者为主
First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.
讲者：Timothy A. Yap, MD, PhD | Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center
摘要号：3010 | Poster Bd #: 208
强效新型CDK2选择性抑制剂PF-07104091在晚期实体瘤患者中首次进行的1/2a期研究，以CDK4/6抑制剂耐药的HR+/HER2-乳腺癌患者为主
First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer.
讲者：Timothy A. Yap, MD, PhD | Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center
摘要号：3011 | Poster Bd #: 209
一项针对转移性三阴性乳腺癌一线治疗的随机、基于分子分型的伞形II期临床FUTURE-SUPER研究
FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer.
讲者：Shao Zhimin, MD | Fudan University Shanghai Cancer Center（复旦大学附属肿瘤医院 邵志敏）
摘要号：3012 | Poster Bd #: 210
Debio 0123-101：Debio 0123联合卡铂治疗晚期实体瘤的1期试验——安全性、药代动力学和初步抗肿瘤活性数据
Debio 0123-101: A phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors—Safety, pharmacokinetic, and preliminary antitumor activity data.
讲者：Hans Gelderblom, MD | Leiden University Medical Center
摘要号：3014 | Poster Bd #: 212
德曲妥珠单抗（T-DXd）对经血浆无细胞DNA（cfDNA）检测确定为HER2扩增的晚期实体瘤的组织不确定性疗效：2期篮子试验结果（ERALD/EPOC1806）
Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).
讲者：Hiroya Taniguchi, MD, PhD | Department of Clinical Oncology, Aichi Cancer Center Hospital
摘要号：3015 | Poster Bd #: 213
新型c-Met靶向抗体-药物偶联物ABBV-400在晚期实体瘤中的首次人体剂量递增研究结果
Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors.
讲者：Manish Sharma, MD | START Midwest
摘要号：3016 | Poster Bd #: 214
一项针对耐药/难治性实体瘤患者靶向 Claudin 18.2 的抗体药物偶联物SYSA1801的首次人体剂量递增和扩展研究
First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.
讲者：Yakun Wang, PhD | Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute（北京大学肿瘤医院 王雅坤）
摘要号：3017 | Poster Bd #: 215
靶向B7-H3抗体药物偶联物HS-20093在晚期实体瘤患者中的I期ARTEMIS-001研究
ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor.
讲者：Jianchun Duan, MD | State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College（中国医学科学院肿瘤医院 段建春）
摘要号：3018 | Poster Bd #: 216
新型口服生物小分子STAT3抑制剂TTI-101用于晚期实体瘤患者的1期试验评估
Phase 1 trial evaluating TTI-101, a first-in-class, orally bioavailable, small molecule, inhibitor of STAT3, in patients with advanced solid tumors.
讲者：Apostolia Maria Tsimberidou, MD, PhD, FASCO | University of Texas MD Anderson Cancer Center
摘要号：3019 | Poster Bd #: 217
tinengotinib单药或联合治疗晚期实体瘤的初步安全性和疗效：Ib/II期临床试验
Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors: A phase Ib/II clinical trial.
讲者：Milind M. Javle, MD | The University of Texas MD Anderson Cancer Center
摘要号：3020 | Poster Bd #: 218
SHP2抑制剂PF-07284892单药或与不同靶向疗法联合治疗肿瘤基因驱动的耐药性实体瘤的首次人体1期研究
A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors.
讲者：Alexander E. Drilon, MD | Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College
口头摘要专场（Oral Abstract Session）
摘要号：LBA3000
德曲妥珠单抗（T-DXd）在HER2表达的实体瘤患者中的疗效和安全性： DESTINY-PanTumor02（DP-02）中期结果
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
讲者：Funda Meric-Bernstam, MD | University of Texas MD Anderson Cancer Center
摘要号：3001
首创新药 EGFR×HER3 双特异性抗体药物偶联物BL-B01D1在局晚期或转移性实体瘤患者中的I期研究
BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.
讲者：Li Zhang, MD | Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center（中山大学肿瘤防治中心 张力）
摘要号：3002
癫痫相关同源蛋白6（SEZ6）靶向抗体药物偶联物ABBV-011在小细胞肺癌患者中的首次人体研究
First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung cancer.
讲者：Daniel Morgensztern, MD | Washington University School of Medicine
摘要号：3003
使用pH值敏感的成像剂pegsitacianine检测细胞还原手术中的腹膜转移：2期研究的最终结果
Detection of peritoneal metastases during cytoreductive surgery using pegsitacianine, a pH sensitive imaging agent: Final results from a phase 2 study.
讲者：Patrick Wagner, MD | Allegheny Health Network Cancer Institute
摘要号：3004
美国癌症协会（ACS）癌症预防研究-3（CPS-3）队列中甲基化DNA生物标志物与癌症发病率
Methylated DNA biomarkers and incident cancer in the American Cancer Society (ACS) Cancer Prevention Study-3 (CPS-3) cohort.
讲者：Alpa Patel, PhD | American Cancer Society
摘要号：3005
肿瘤分数改善肿瘤学早期临床试验的患者选择：两项精准医学研究的分析
Tumor fraction to improve patient selection for oncology early phase clinical trials: Analysis of two precision medicine studies.
讲者：Sophie Cousin, MD | Early Phase Clinical Trials Unit and Thoracic Unit, Institut Bergonié
摘要号：3006
新型BRAF抑制剂FORE8394在晚期实体瘤和中枢神经系统肿瘤患者中的安全性和疗效：1/2a期研究结果
Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study.
讲者：Macarena Ines De La Fuente, MD | Sylvester Comprehensive Cancer Center, University of Miami
摘要号：3007
新一代RET抑制剂KL590586在RET改变的实体瘤中的I期研究
A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors.
讲者：Qing Zhou, MD, PhD | Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University（广东省人民医院 周清）
摘要号：3008
蛋白精氨酸甲基转移酶5（PRMT5）脑渗透抑制剂PRT811在复发性高级别神经胶质瘤或葡萄膜黑色素瘤（UM）患者中的1期研究
A phase 1 study of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients (pts) with recurrent high-grade glioma or uveal melanoma (UM).
讲者：Varun Monga, MBBS | University of Iowa
（本文依照报告日期和出场排序整理，如有错误或遗漏，敬请留言指正。）
https://meetings.asco.org/meetings/2023-asco-annual-meeting/299/program-guide/scheduled-sessions?filters=%7B%22track%22:%5B%7B%22key%22:%22Developmental%20Therapeutics%E2%80%94Molecularly%20Targeted%20Agents%20and%20Tumor%20Biology%22%7D%5D%7D
排版编辑：肿瘤资讯-云初
苏公网安备 32059002004080号
